EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and Spinocerebellar ataxias.

The company’s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for Alzheimer’s disease, a Histone Deacetylase (HDAC) Program for Huntington’s disease and a Neuroprotection Program (EVPK-0003546) for Huntington’s disease as well as other neurodegenerative indications.